Intra-and extracellular activity of linezolid against Staphylococcus aureus in vivo and in vitro

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 5, 2010, Pages 962-973

  Sandberg, Anne ^a   Jensen, Klaus Skovbo ^a   Baudoux, Pierre ^b   van Bambeke, Françoise ^b   Tulkens, Paul M ^b   Frimodt Møller, Niels ^a  

^a STATENS SERUM INSTITUT   (Denmark)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Intracellular antimicrobial activity; Intracellular S. aureus; Mouse peritonitis model; Non linear pharmacokinetics; Pharmacodynamics; Protein binding; THP 1 cells

Indexed keywords

LINEZOLID; ACETAMIDE DERIVATIVE; ANTIINFECTIVE AGENT; OXAZOLIDINONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL PERITONITIS; BACTERICIDAL ACTIVITY; COLONY FORMING UNIT; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG TREATMENT FAILURE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; TREATMENT OUTCOME; ANIMAL; DRUG EFFECT; PERITONITIS; STAPHYLOCOCCUS AUREUS;

ACETAMIDES; ANIMALS; ANTI-BACTERIAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MICE; OXAZOLIDINONES; PERITONITIS; STAPHYLOCOCCUS AUREUS;

EID: 77953708769     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq052     Document Type: Article

References (53)

1. Kuehnert MJ, Hill HA, Kupronis BA et al. Methicillin-resistant-Staphylococcus aureus hospitalizations, United States. Emerg Infect Dis 2005; 11: 868-72.
2. Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998; 339: 520-32.
3. Bamberger DM, Boyd SE. Management of Staphylococcus aureus infections. Am Fam Physician 2005; 72: 2474-81.
4. Iyer S, Jones DH. Community-acquired methicillin-resistant Staphylococcus aureus skin infection: a retrospective analysis of clinical presentation and treatment of a local outbreak. J Am Acad Dermatol 2004; 50: 854-8.
5. Ferrara AM. Treatment of hospital-acquired pneumonia caused by methicillin-resistant Staphylococcus aureus. Int J Antimicrob Agents 2007; 30: 19-24.
6. Risson DC, O'Connor ED, Guard RW et al. A fatal case of necrotising pneumonia due to community-associated methicillin-resistant Staphylococcus aureus. Med J Aust 2007; 186: 479-80.
7. Fowler VG Jr, Miro JM, Hoen B et al. Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA 2005; 293: 3012-21.
8. Roder BL, Wandall DA, Frimodt-Moller N et al. Clinical features of Staphylococcus aureus endocarditis: a 10-year experience in Denmark. Arch Intern Med 1999; 159: 462-9.
9. Ellington JK, Harris M, Webb L et al. Intracellular Staphylococcus aureus. A mechanism for the indolence of osteomyelitis. J Bone Joint Surg Br 2003; 85: 918-21.
10. Jensen AG, Espersen F, Skinhoj P et al. Bacteremic Staphylococcus aureus spondylitis. Arch Intern Med 1998; 158: 509-17.
11. Pedersen M, Benfield TL, Skinhoej P et al. Haematogenous Staphylococcus aureus meningitis. A 10-year nationwide study of 96 consecutive cases. BMC Infect Dis 2006; 6: 49.
12. Chang FY, Peacock JE Jr, Musher DM et al. Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine (Baltimore) 2003; 82: 333-9.
13. Ciampolini J, Harding KG. Pathophysiology of chronic bacterial osteomyelitis. Why do antibiotics fail so often? Postgrad Med J 2000; 76: 479-83.
14. Johnson LB, Almoujahed MO, Ilg K et al. Staphylococcus aureus bacteremia: compliance with standard treatment, long-term outcome and predictors of relapse. Scand J Infect Dis 2003; 35: 782-9.
15. Sanabria TJ, Alpert JS, Goldberg R et al. Increasing frequency of staphylococcal infective endocarditis. Experience at a university hospital, 1981 through 1988. Arch Intern Med 1990; 150: 1305-9.
16. Watanakunakorn C. Staphylococcus aureus endocarditis at a community teaching hospital, 1980 to 1991. An analysis of 106 cases. Arch Intern Med 1994; 154: 2330-5.
17. Brouillette E, Grondin G, Shkreta L et al. In vivo and in vitro demonstration that Staphylococcus aureus is an intracellular pathogen in the presence or absence of fibronectin-binding proteins. Microb Pathog 2003; 35: 159-68.
18. Clement S, Vaudaux P, Francois P et al. Evidence of an intracellular reservoir in the nasal mucosa of patients with recurrent Staphylococcus aureus rhinosinusitis. J Infect Dis 2005; 192: 1023-8.
19. Gresham HD, Lowrance JH, Caver TE et al. Survival of Staphylococcus aureus inside neutrophils contributes to infection. J Immunol 2000; 164: 3713-22.
20. Hess DJ, Henry-Stanley MJ, Erickson EA et al. Intracellular survival of Staphylococcus aureus within cultured enterocytes. J Surg Res 2003; 114: 42-9.
21. Lowy FD. Is Staphylococcus aureus an intracellular pathogen? Trends Microbiol 2000; 8: 341-3.
22. Mempel M, Schnopp C, Hojka M et al. Invasion of human keratinocytes by Staphylococcus aureus and intracellular bacterial persistence represent haemolysin-independent virulence mechanisms that are followed by features of necrotic and apoptotic keratinocyte cell death. Br J Dermatol 2002; 146: 943-51.
23. Tulkens PM. Intracellular distribution and activity of antibiotics. Eur J Clin Microbiol Infect Dis 1991; 10: 100-6.
24. Van Bambeke F, Barcia-Macay M, Lemaire S et al. Cellular pharmacodynamics and pharmacokinetics of antibiotics: current views and perspectives. Curr Opin Drug Discov Devel 2006; 9: 218-30.
25. Barcia-Macay M, Seral C, Mingeot-Leclercq MP et al. Pharmacodynamic evaluation of the intracellular activities of antibiotics against Staphylococcus aureus in a model of THP-1 macrophages. Antimicrob Agents Chemother 2006; 50: 841-51.
26. Sandberg A, Hessler JH, Skov RL et al. Intracellular activity of antibiotics against Staphylococcus aureus in a mouse peritonitis model. Antimicrob Agents Chemother 2009; 53: 1874-83.
27. Van Bambeke F, Carryn S, Seral C et al. Cellular pharmacokinetics and pharmacodynamics of the glycopeptide antibiotic oritavancin (LY333328) in a model of J774 mouse macrophages. Antimicrob Agents Chemother 2004; 48: 2853-60.
28. Lemaire S, Van Bambeke F, Appelbaum PC et al. Cellular pharmacokinetics and intracellular activity of torezolid (TR-700): studies with human macrophage (THP-1) and endothelial (HUVEC) cell lines. J Antimicrob Chemother 2009; 64: 1035-43.
29. Lemaire S, Van Bambeke F, Tulkens PM. Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages. Antimicrob Agents Chemother 2009; 53: 3734-43.
30. Stalker DJ, Jungbluth GL. Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin Pharmacokinet 2003; 42: 1129-40.
31. Schmidt-Ioanas M, de Roux A, Lode H. New antibiotics for the treatment of severe staphylococcal infection in the critically ill patient. Curr Opin Crit Care 2005; 11: 481-6.
32. Swaney SM, Aoki H, Ganoza MC et al. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob Agents Chemother 1998; 42: 3251-5.
33. Bozdogan B, Appelbaum PC. Oxazolidinones: activity, mode of action, and mechanism of resistance. Int J Antimicrob Agents 2004; 23: 113-9.
34. Ford CW, Zurenko GE, Barbachyn MR. The discovery of linezolid, the first oxazolidinone antibacterial agent. Curr Drug Targets Infect Disord 2001; 1: 181-99.
35. Dresser LD, Rybak MJ. The pharmacologic and bacteriologic properties of oxazolidinones, a new class of synthetic antimicrobials. Pharmacotherapy 1998; 18: 456-62.
36. Marchese A, Schito GC. The oxazolidinones as a new family of antimicrobial agent. Clin Microbiol Infect 2001; 7 Suppl 4: 66-74.
37. Carryn S, Van Bambeke F, Mingeot-Leclercq MP et al. Comparative intracellular (THP-1 macrophage) and extracellular activities of b-lactams, azithromycin, gentamicin, and fluoroquinolones against Listeria monocytogenes at clinically relevant concentrations. Antimicrob Agents Chemother 2002; 46: 2095-103.
38. Elliott GR, Peterson PK, Verbrugh HA et al. Influence of subinhibitory concentrations of penicillin, cephalothin, and clindamycin on Staphylococcus aureus growth in human phagocytic cells. Antimicrob Agents Chemother 1982; 22: 781-4.
39. Qazi SN, Counil E, Morrissey J et al. agr expression precedes escape of internalized Staphylococcus aureus from the host endosome. Infect Immun 2001; 69: 7074-82.
40. Seral C, Van Bambeke F, Tulkens PM. Quantitative analysis of gentamicin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin (LY333328) activities against intracellular Staphylococcus aureus in mouse J774 macrophages. Antimicrob Agents Chemother 2003; 47: 2283-92.
41. Mouton JW, Dudley MN, Cars O et al. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for antiinfective drugs: an update. J Antimicrob Chemother 2005; 55: 601-7.
42. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Fifteenth Informational Supplement M100-S15. CLSI, Wayne, PA, USA, 2008.
43. Tsuchiya S, Yamabe M, Yamaguchi Y et al. Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). Int J Cancer 1980; 26: 171-6.
44. Lemaire S, Van Bambeke F, Mingeot-Leclercq MP et al. Activity of three β-lactams (ertapenem, meropenem and ampicillin) against intraphagocytic Listeria monocytogenes and Staphylococcus aureus. J Antimicrob Chemother 2005; 55: 897-904.
45. Scorneaux B, Ouadrhiri Y, Anzalone G et al. Effect of recombinant human gamma interferon on intracellular activities of antibiotics against Listeria monocytogenes in the human macrophage cell line THP-1. Antimicrob Agents Chemother 1996; 40: 1225-30.
46. Frimodt-Moller N. The mouse peritonitis model: present and future use. J Antimicrob Chemother 1993; 31 Suppl D: 55-60.
47. Andes D, Craig WA. Animal model pharmacokinetics and pharmacodynamics: a critical review. Int J Antimicrob Agents 2002; 19: 261-8.
48. Barcia-Macay M, Lemaire S, Mingeot-Leclercq MP et al. Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. J Antimicrob Chemother 2006; 58: 1177-84.
49. Andes D, van Ogtrop ML, Peng J et al. In vivo pharmacodynamics of a new oxazolidinone (linezolid). Antimicrob Agents Chemother 2002; 46: 3484-9.
50. Gee T, Ellis R, Marshall G et al. Pharmacokinetics and tissue penetration of linezolid following multiple oral doses. Antimicrob Agents Chemother 2001; 45: 1843-6.
51. Stevens DL, Herr D, Lampiris H et al. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002; 34: 1481-90.
52. Kaplan SL, Deville JG, Yogev R et al. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. Pediatr Infect Dis J 2003; 22: 677-86.
53. Weigelt J, Itani K, Stevens D et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2005; 49: 2260-6.